Total patients: n = 148 | n | % |
---|---|---|
BCS | 143 | 96.6 |
ME | 4 | 2.7 |
no surgery | 1 | 0.7 |
TNM classification | ||
PTis | 17 | 11.5 |
pT1 | 100 | 67.6 |
pT2 | 29 | 19.6 |
pT3 | 1 | 0.7 |
pT4 | 1 | 0.7 |
N0 | 130 | 87.8 |
N1a | 18 | 12.2 |
M0 | 147 | 99.3 |
M1 | 1 | 0.7 |
Resection status | ||
R0 | 128 | 86.5 |
initially R1, after second resection R0 | 19 | 12.8 |
no resection | 1 | 0.7 |
Grading | ||
G1 | 26 | 17.6 |
G2 | 80 | 54.1 |
G3 | 38 | 25.7 |
not specified | 4 | 2.7 |
Hormone receptor status | ||
ER | ||
positive | 131 | 88.5 |
negative | 17 | 11.5 |
not specified | 0 | 0 |
PR | ||
positive | 121 | 81.8 |
negative | 27 | 18.2 |
not specified | 0 | 0 |
Ki-67 Score | ||
low (< 10%) | 13 | 8.8 |
intermediate (10–25%) | 58 | 39.2 |
high (> 25%) | 62 | 41.9 |
not specified | 15 | 10.1 |
HER2 status | ||
0 | 47 | 31.8 |
1 + | 52 | 35.1 |
2 + | 20 | 13.5 |
3 + | 13 | 8.8 |
not specified | 16 | 10.8 |
TNBC | 10 | 6.8 |
Radiotherapy | ||
Conventional fractionation | 114 | 77 |
Moderate hypofractionation | 34 | 23 |
SIB | 46 | 31.1 |
IORT | 53 | 35.8 |
3DRT | 148 | 100 |
DIBH | 131 | 88.5 |
FB | 17 | 11.5 |
SLND | ||
Yes | 122 | 82.4 |
No | 18 | 12.2 |
ALND | 8 | 5.4 |
Chemotherapy | ||
Neoadjuvant | 24 | 16.2 |
Adjuvant | 32 | 21.6 |
Endocrine therapy | 116 | 78.4 |